Activation of the PI3K/AKT/mTOR pathway is considered to play a crucial role in human neoplasms and so numerous drugs targeting this pathway have been developed and are currently in clinical trials [6, 41–43] including HNSCC (reviewed in [44]. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.